State Board of Administration of Florida Retirement System Has $1,187,000 Position in Halozyme Therapeutics, Inc. (HALO)

State Board of Administration of Florida Retirement System maintained its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 91,554 shares of the biopharmaceutical company’s stock at the end of the first quarter. State Board of Administration of Florida Retirement System’s holdings in Halozyme Therapeutics were worth $1,187,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HALO. Russell Investments Group Ltd. acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $602,000. State Street Corp raised its stake in shares of Halozyme Therapeutics by 17.1% in the fourth quarter. State Street Corp now owns 3,819,690 shares of the biopharmaceutical company’s stock worth $37,742,000 after buying an additional 558,479 shares during the last quarter. Oxford Asset Management acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $1,752,000. Trexquant Investment LP acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $346,000. Finally, Dynamic Technology Lab Private Ltd raised its stake in shares of Halozyme Therapeutics by 75.0% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 19,589 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 8,396 shares during the last quarter. Hedge funds and other institutional investors own 81.77% of the company’s stock.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened at 12.85 on Tuesday. Halozyme Therapeutics, Inc. has a 12-month low of $7.70 and a 12-month high of $15.20. The firm’s 50 day moving average is $13.37 and its 200 day moving average is $12.58. The company’s market cap is $1.65 billion.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.01. The company had revenue of $29.60 million for the quarter, compared to analysts’ expectations of $30.79 million. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 86.80%. The firm’s revenue for the quarter was down 30.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.16) EPS. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post ($1.00) EPS for the current fiscal year.

WARNING: This news story was originally published by Mideast Time and is owned by of Mideast Time. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.mideasttime.com/state-board-of-administration-of-florida-retirement-system-has-1187000-position-in-halozyme-therapeutics-inc-halo/1775214.html.

A number of equities research analysts have issued reports on the company. BMO Capital Markets assumed coverage on Halozyme Therapeutics in a research note on Monday, April 17th. They issued a “market perform” rating and a $14.00 price target for the company. Zacks Investment Research upgraded Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, April 3rd. ValuEngine upgraded Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Deutsche Bank AG increased their price target on Halozyme Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, March 30th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $14.46.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:HALO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.